Barcelona, Spain

Magí Ferre Albaladejo


Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Magí Ferre Albaladejo: Innovator in Fatty Acid Amides

Introduction

Magí Ferre Albaladejo is a notable inventor based in Barcelona, Spain. He has made significant contributions to the field of biomedical research, particularly in the treatment of liver diseases. His innovative work has led to the development of a patent that addresses critical health issues related to fatty liver conditions.

Latest Patents

Magí Ferre Albaladejo holds a patent for "Fatty acid amides for the prevention and/or treatment of steatohepatitis." This invention focuses on the use of fatty acid amides combined with phenylalkylamines in pharmaceutical compositions. The aim is to prevent and treat fatty liver diseases, including both alcoholic and non-alcoholic steatohepatitis (NASH). This patent represents a significant advancement in the therapeutic options available for these conditions.

Career Highlights

Throughout his career, Albaladejo has worked with prominent research institutions. He has been associated with the Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (Fimabis) and the Consejo Superior de Investigaciones Científicas. His work in these organizations has contributed to the advancement of biomedical research and innovation.

Collaborations

Magí Ferre Albaladejo has collaborated with esteemed colleagues in his field, including Fernando Rodríguez De Fonseca and Francisco Javier Pavón Morón. These collaborations have further enriched his research and have led to impactful developments in the treatment of liver diseases.

Conclusion

Magí Ferre Albaladejo is a distinguished inventor whose work in fatty acid amides has the potential to transform the treatment landscape for liver diseases. His contributions to biomedical research highlight the importance of innovation in addressing critical health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…